Minireviews
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 24, 2025; 16(8): 107490
Published online Aug 24, 2025. doi: 10.5306/wjco.v16.i8.107490
Recent progress in the use of periplocin, periplocymarin and periplogenin in cancer treatment
Xin Sun, Xiao-Wei Shi, Lei Han, Yi-Fan Zhang, Yang Xu, Yu-Cheng Lu
Xin Sun, Xiao-Wei Shi, Medical College, Linyi University, Linyi 276000, Shandong Province, China
Xin Sun, Lei Han, Yu-Cheng Lu, Department of Biobank, Linyi People’s Hospital, Linyi 276000, Shandong Province, China
Yi-Fan Zhang, International School of Bioresource Application, Linyi University, Linyi 276000, Shandong Province, China
Yang Xu, Department of Reproductive Medicine, Linyi People’s Hospital, Linyi 276000, Shandong Province, China
Co-corresponding authors: Yang Xu and Yu-Cheng Lu.
Author contributions: Sun X and Shi XW were responsible for the organization of the article and literature survey; Sun X and Han L drafted the original manuscript; Sun X, Zhang YF, Xu Y, and Lu YC revised and edited the draft; All authors have read and approved the final manuscript.
Supported by Traditional Chinese Medicine Science and Technology Project of Shandong Province, China, No. M-2023131; and The Science and Technology Development Fund Project of the Affiliated Hospital of Xuzhou Medical University, China, No. XYFM202348.
Conflict-of-interest statement: The authors declare no conflict of interests for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yu-Cheng Lu, PhD, Senior Researcher, Department of Biobank, Linyi People's Hospital, No. 27 Jiefang Road, Lanshan District, Linyi 276000, Shandong Province, China. luyu-20@163.com
Received: March 30, 2025
Revised: May 3, 2025
Accepted: June 26, 2025
Published online: August 24, 2025
Processing time: 145 Days and 0.3 Hours
Core Tip

Core Tip: Periplocin, periplocymarin and periplogenin are three cardiac glycosides widely recognized as the main active ingredients of Cortex Periplocae. Various experiments have shown that they exert antitumor effects by regulating cell cycle proteins, blocking malignant cell proliferation, activating caspase proteases and inducing apoptosis in cancer cells. This minireview focuses on the tumor inhibitory effects of periplocin, periplocymarin and periplogenin.